Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, dose-escalation Phase 1/1b study in patients with acute
myelogenous leukemia (AML)/MDS or non-Hodgkin Lymphoma (NHL), intended to investigate safety,
pharmacokinetics, and the pharmacodynamic effects of FT-1101 administered via one or more
intermittent dosing schedules alone and in combination with azacitidine. Once the MTD has
been established for a treatment cohort, up to 20 additional patients may be enrolled in up
to 4 expansion cohorts each of select populations of patients with either AML/MDS or NHL at
the recommended dose for future studies to confirm safety.